Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

Phase 4

Completed

Conditions: Post-Menopausal Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]
Drug: Alendronate

First Posted Date: 2007-07-18

Last Posted Date: 2011-06-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 801

Registration Number: NCT00503113

A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Rituximab [MabThera/Rituxan]

First Posted Date: 2007-07-18

Last Posted Date: 2017-08-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 215

Registration Number: NCT00503425

Locations: 🇮🇱
Carmel Hospital; Rheumatology Dept, Haifa, Israel
🇮🇱
Meir Medical Center; Internal Dept A, Kfar Saba, Israel
🇮🇱
EMMS Nazareth; Internal Department A, Nazareth, Israel

and more 13 locations

A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: rituximab [MabThera/Rituxan]
Drug: Methotrexate

First Posted Date: 2007-07-18

Last Posted Date: 2017-08-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 10

Registration Number: NCT00502853

Locations: 🇮🇹
Università Degli Studi Di Genova - Dimi; Reumatologia, Genova, Liguria, Italy

Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy

Phase 2

Completed

Conditions: Diabetic Neuropathy

Interventions: Drug: Experimental
Drug: Placebo comparator

First Posted Date: 2007-07-04

Last Posted Date: 2016-11-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 159

Registration Number: NCT00496457

Locations: 🇭🇷
Genaral Hospital "Josip Bencevic", Internal Medicine Department-Unit for Diabetes, Andrije Stampara 42, Slavonski Brod, Croatia
🇭🇷
General Hospital Varazdin, Internal Medicine Department-Unit for Diabetes, Ivana Mestrovica bb, Varazdin, Croatia
🇷🇸
Center for Neurology, Clinical Centre "Kragujevac", Kragujevac, Serbia

and more 28 locations

BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: ibandronate [Bonviva/Boniva]
Drug: Placebo

First Posted Date: 2007-06-28

Last Posted Date: 2016-03-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 68

Registration Number: NCT00493623

A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Conditions: Postmenopausal Osteoporosis

First Posted Date: 2007-06-28

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00493532

A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: RG1530

First Posted Date: 2007-06-28

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 48

Registration Number: NCT00493155

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

Phase 4

Terminated

Conditions: HIV Infections

Interventions: Drug: enfuvirtide [Fuzeon]
Drug: Optimized background ARV
Drug: Integrase inhibitor

First Posted Date: 2007-06-19

Last Posted Date: 2011-07-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 29

Registration Number: NCT00488059

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: peginterferon alfa-2a [Pegasys]

First Posted Date: 2007-06-19

Last Posted Date: 2017-04-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 18

Registration Number: NCT00487747

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Phase 3

Terminated

Conditions: B-cell Lymphoma

Interventions: Drug: Rituximab
Drug: Bevacizumab
Drug: CHOP
Drug: Placebo

First Posted Date: 2007-06-15

Last Posted Date: 2017-07-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 787

Registration Number: NCT00486759

Locations: 🇫🇷
Hopital Saint Jean; Hematologie, Perpignan, France
🇺🇸
Uni of California - San Diego; Cancer Center & Dept of Medicine, La Jolla, California, United States
🇺🇸
Kenmar Research Inst., Whittier, California, United States

and more 263 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy